Obesity Management: Exploring Amylin-Based Therapies
This activity is supported by an educational grant from Novo Nordisk, Inc.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an educational grant from Novo Nordisk, Inc.
Activity Description
Advancements in obesity research have revolutionized our understanding of the disease as a complex disorder of energy dysregulation, paving the way for novel therapeutic approaches. Among these, amylin—a key hormone involved in satiety and energy regulation—has emerged as a promising new target for obesity treatment. Now, clinician awareness of amylin's role and its potential is on the rise. The Amylin Adventure is an engaging program designed to equip healthcare professionals with cutting-edge knowledge of amylin biology and its therapeutic implications. Participants will explore the intricate hormonal regulation of obesity in a unique and memorable way. Key topics of this activity include amylin’s role in the metabolic processes underlying obesity, emerging amylin-based therapies, and the latest clinical evidence supporting their potential role in obesity management. A panel discussion will also provide insights into the future integration of amylin-targeting therapies within clinical practice. This engaging and informative activity will enhance clinicians' ability to evaluate and apply emerging treatments to their patients with obesity, ultimately improving outcomes for individuals struggling with this chronic disease.
Target Audience
The intended audience for this activity includes endocrinology, obesity, primary care, and pediatrics physicians as well as pharmacists involved in the management of patients with obesity.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Summarize the physiological role of amylin in obesity regulation.
- Outline the mechanism of action of amylin-based therapies and how they contribute to improved obesity management.
- Assess the most recent clinical data on emerging amylin-based therapies for patients with obesity.
Activity Chair
Jaime Almandoz, MD, MBA, FTOS
Medical Director, Weight Wellness Program
Professor of Internal Medicine
Division of Endocrinology
University of Texas Southwestern Medical Center
Dallas, TX
Faculty
Deborah B. Horn, DO, MPH, MFOMA
Professor
University of Texas McGovern Medical School, Department of Surgery
Medical Director
Center for Obesity Medicine and Metabolic Performance
Program Director
UT Fellowship in Clinical Obesity Medicine
Houston, TX
Robert F. Kushner, MD, MS, FACP, FTOS, DABOM
Professor Emeritus, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Former Director, Center for Lifestyle Medicine
Northwestern Medicine
Chicago, IL
Domenica Rubino, MD
Director
Washington Center for Weight Management and Research
Arlington, VA
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Frederick, PharmD, BCPS
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
- 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
- 1.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program.
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.
This program is acceptable for 1.25 contact hour of ACPE Continuing Education Credit. The ACPE Universal Program Number is JA0006104-0000-25-025-H01-P, effective 12/31/2025. This is a knowledge-based activity, and there is no fee to attend.
*IMPORTANT* Pharmacists MUST request credit within 60 days of activity completion. Upon receipt of the completed activity evaluation form, transcript information will be available at CPE Monitor within 4 weeks.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, December 31, 2025, to December 30, 2026.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objective, answer the polling and pretest questions, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate or CPE Statement of Credit.
In addition to providing a downloadable certificate, CME Providers accredited by the Accreditation Council for Continuing Medical Education (ACCME) have the ability to transmit CME credit data for all US physicians to an online repository, the ACCME Program and Activity Reporting System (PARS). CME credit data submitted to PARS can be viewed, managed, and tracked by US physicians in "CME Passport," a free, centralized web application.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Jaime Almandoz, MD, MBA, FTOS
Consultant: AbbVie, Amgen, Boehringer Ingelheim, Kailera, Lilly, Nestle, Novo Nordisk, Rivus, Rhythm
Deborah B. Horn, DO, MPH, MFOMA
Advisor: Amgen, AstraZeneca, Boehringer Ingelheim, Lilly, Novo Nordisk, Zealand
Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, Lilly, Novo Nordisk, Zealand
Speaker Contracted by Ineligible Company: Lilly, Novo Nordisk
Independent Research Contractor (paid to institution): KVK Tech, Lilly, Novo Nordisk, Weight Watchers
Robert F. Kushner, MD, MS, FACP, FTOS, DABOM
Advisor: Altimmune, Antag, AstraZeneca, Boehringer Ingelheim, Currax, Lilly, Novo Nordisk, Regeneron, Structure, Weight Watchers
Speaker Contracted by Ineligible Company: Novo Nordisk
Domenica Rubino, MD
Advisor: AbbVie, AstraZeneca, Boehringer Ingelheim, Cytoki, Ferring, Lilly, Neurocrine, Novo Nordisk, Pfizer, Regeneron, Roche, Shionogi
Consultant: AbbVie, AstraZeneca, Boehringer Ingelheim, Cytoki, Ferring, Lilly, Neurocrine, Novo Nordisk, Pfizer, Regeneron, Roche, Shionogi
Speaker Contracted by Ineligible Company: Novo Nordisk
Independent Research Contractor: Amgen, AstraZeneca, Boehringer Ingelheim, Novo Nordisk
Individual Stocks (publicly traded): AbbVie
Planners/Reviewers reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2025 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by contacting our designated copyright agent (as outlined below). In your email, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (e.g., URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you are either the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614
CE Questions?
Contact us at cme@vindicoCME.com